Sort by
Refine Your Search
-
Listed
-
Country
-
Field
-
or translational research experience Knowledge of machine learning, Bayesian modeling, or statistical method development Ideal Personal Attributes: Independent, proactive, and scientifically curious Detail-oriented
-
for early cancer detection, prognosis, and predictive responses to chemotherapies and targeted drugs. Studying the genetic and epigenetic basis of GI cancers (e.g., aberrant DNA methylation, histone
-
well as developing new targeted therapies for hematological malignant diseases and cancers. Our research involves experiments with various biochemistry and molecular techniques, genomic approaches, and genetic and
-
targets. * Participate in the collection, processing, and cataloging of clinical samples in collaboration with Ophthalmology colleagues. * Contribute to grant applications, manuscript preparation, and
-
identifying novel biomarkers and drug targets. Expand and improve skills: disease models based on genome-modified animals and human iPSCs and 3D-organoids, genetic/epigenetic modification, behavioral
-
organoids and co-culture systems. Key Responsibilities & Activities Process patient biopsies/PBMCs, generate single-cell datasets (scRNA/CITE-seq), and identify testable pathways. Validate targets in tissue
-
developing drugs for the treatment of cancer, vascular anomalies, macular degeneration and glaucoma. The group is dedicated to identifying novel targets, pursuing high throughput screening of therapeutics and
-
interception studies aimed at identifying biological and behavioral targets for preventing progression from premalignant to invasive disease Integration of lifestyle, metabolic, and genomic data to refine early
-
state-of-the-art genome engineering, molecular biology, and high-throughput tools to drive discovery and characterisation of new molecular targets both within the sensory nervous system and in other
-
of aging and Alzheimer's disease that have now started yielding important insights into the pathophysiology of Alzheimer's disease using both targeted and unbiased high throughput protein assays. We are in